PMI Biopharma Solutions and Nashville Biosciences announced a strategic collaboration to provide their customers with an integrated product offering around drug discovery and development.
Under this alliance, both organizations will have the opportunity to bundle Nashville Bioscience's data and in silico technology with PMI's comprehensive laboratory services and scientific expertise to experimentally test mechanistic & therapeutic hypotheses for a comprehensive drug target identification and validation package.
"With both organizations located in Nashville it was an easy decision to pair our capabilities to better serve our clients. This alliance will allow clients a smooth transition from in silico to in vitro studies," said Dr. David Sunseri, CEO, PMI Biopharma Solutions.
"Our respective capabilities fit together very nicely to advance our clients' research & development in the life sciences. We are excited to collaborate with PMI Biopharma Solutions to better serve our clients.” Dr. Leeland Ekstrom, Chief Operating Officer and Founder of Nashville Biosciences, said.